https://orcid.org/0000-0001-5571-7592
Abstract
Background
Using medicines regularly can be a burden for some people and can contribute to reduced adherence. In New Zealand, relatively few studies have examined people’s medicine-taking experiences and most involved older people, although medicine burden is also an issue for younger people. The UK-developed “Living with Medicines Questionnaire” (LMQ-3) is an instrument designed to quantify medicine burden.
Objective
The objective was to quantify medicines burden among New Zealand adults, using the LMQ-3, to identify any sub-populations with high medicine burden and to identify specific issues that may need to be addressed.
Setting
The study was set in New Zealand and included seven national patient support group websites, and five community pharmacies in Dunedin.
Methods
The survey was distributed to adults ≥18 years using ≥ one medicine for ≥3 months. LMQ-3 scores and domain scores were compared by patient characteristics using descriptive statistics and statistical tests.
Results
In total, 472 responses were analysed: 327/417 (78.4%) from patient support group websites and 145/360 (40.3%) from community pharmacies. Most commonly participants were female (295, 62.5%), ≥65 years (236, 50.0%), European (422, 89.4%), retired (232, 49.2%), university educated (203, 43.0%), used medicines independently (449, 95.1%), and paid for prescriptions (429, 90.9%). Most used <10 medicines (415, 87.9%) and <three times daily (356, 75.4%). From LMQ scores, 30.5% had a high burden (≥111). Regression analysis indicated that higher LMQ-3 scores were associated with those who were unemployed, aged 18–29 years, using ≥5 medicines, or using medicines <3 times a day (p<0.01). Burden was mainly driven by a perceived lack of autonomy over medicine regimens, or concerns about medicines and side effects.
Conclusion
Three quarters of New Zealand participants experienced moderate or high medicine burden. Being unemployed, aged 18–29 years, or using more (or more frequent) medicines, were associated with higher burden. These groups should become the target for interventions seeking to reduce medicine burden.
Acknowledgments
We thank the study participants, the patient support group websites, and the community pharmacy managers that permitted survey distribution.
Funding
The New Zealand Pharmacy Education Foundation provided funding to support the study.
Disclosure
The authors have no conflicts of interest to declare.